Literature DB >> 22528274

Guidelines for the evaluation and management of status epilepticus.

Gretchen M Brophy1, Rodney Bell, Jan Claassen, Brian Alldredge, Thomas P Bleck, Tracy Glauser, Suzette M Laroche, James J Riviello, Lori Shutter, Michael R Sperling, David M Treiman, Paul M Vespa.   

Abstract

Status epilepticus (SE) treatment strategies vary substantially from one institution to another due to the lack of data to support one treatment over another. To provide guidance for the acute treatment of SE in critically ill patients, the Neurocritical Care Society organized a writing committee to evaluate the literature and develop an evidence-based and expert consensus practice guideline. Literature searches were conducted using PubMed and studies meeting the criteria established by the writing committee were evaluated. Recommendations were developed based on the literature using standardized assessment methods from the American Heart Association and Grading of Recommendations Assessment, Development, and Evaluation systems, as well as expert opinion when sufficient data were lacking.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22528274     DOI: 10.1007/s12028-012-9695-z

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  243 in total

1.  Midazolam as a first-line agent for status epilepticus in children.

Authors:  H Yoshikawa; S Yamazaki; T Abe; Y Oda
Journal:  Brain Dev       Date:  2000-06       Impact factor: 1.961

2.  Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus.

Authors:  David E Naylor; Hantao Liu; Claude G Wasterlain
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

Review 3.  Continuous EEG monitoring in the intensive care unit: an overview.

Authors:  Lawrence J Hirsch
Journal:  J Clin Neurophysiol       Date:  2004 Sep-Oct       Impact factor: 2.177

4.  Causes and consequences of status epilepticus in adults. A study of 86 cases.

Authors:  J M Oxbury; C W Whitty
Journal:  Brain       Date:  1971       Impact factor: 13.501

Review 5.  The role of benzodiazepines in the management of status epilepticus.

Authors:  D M Treiman
Journal:  Neurology       Date:  1990-05       Impact factor: 9.910

6.  Eight-year study of childhood status epilepticus: midazolam infusion in management and outcome.

Authors:  Roshan Koul; Alexander Chacko; Hashim Javed; Kassim Al Riyami
Journal:  J Child Neurol       Date:  2002-12       Impact factor: 1.987

7.  Predictors of mortality in patients with suspected propofol infusion syndrome.

Authors:  Jeffrey J Fong; Lynne Sylvia; Robin Ruthazer; Greg Schumaker; Marisol Kcomt; John W Devlin
Journal:  Crit Care Med       Date:  2008-08       Impact factor: 7.598

8.  Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus.

Authors:  K B Krishnamurthy; F W Drislane
Journal:  Epilepsia       Date:  1996-09       Impact factor: 5.864

9.  Ten patients with refractory status epilepticus in an intensive care department.

Authors:  J C ter Maaten; R J Strack van Schijndel; J J Heimans; W O Schreuder
Journal:  Neth J Med       Date:  1998-12       Impact factor: 1.422

10.  Status epilepticus at an urban public hospital in the 1980s.

Authors:  D H Lowenstein; B K Alldredge
Journal:  Neurology       Date:  1993-03       Impact factor: 9.910

View more
  342 in total

1.  Guidelines for status epilepticus: are we there yet?

Authors:  Simon Shorvon
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

2.  Periodic Assessment of the Use of Continuous EEG Monitoring.

Authors:  David Spencer
Journal:  Epilepsy Curr       Date:  2015 Jul-Aug       Impact factor: 7.500

3.  High-dose midazolam infusion for refractory status epilepticus.

Authors:  Andres Fernandez; Hector Lantigua; Christine Lesch; Belinda Shao; Brandon Foreman; J Michael Schmidt; Lawrence J Hirsch; Stephan A Mayer; Jan Claassen
Journal:  Neurology       Date:  2013-12-20       Impact factor: 9.910

Review 4.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 5.  [Diagnosis and treatment of status epilepticus in the intensive care unit].

Authors:  W Müllges
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-05-03       Impact factor: 0.840

6.  Therapeutic coma for status epilepticus: Differing practices in a prospective multicenter study.

Authors:  Vincent Alvarez; Jong Woo Lee; M Brandon Westover; Frank W Drislane; Jan Novy; Mohamed Faouzi; Nicola A Marchi; Barbara A Dworetzky; Andrea O Rossetti
Journal:  Neurology       Date:  2016-09-24       Impact factor: 9.910

7.  Nonconvulsive seizures in subarachnoid hemorrhage link inflammation and outcome.

Authors:  Jan Claassen; David Albers; J Michael Schmidt; Gian Marco De Marchis; Deborah Pugin; Christina Maria Falo; Stephan A Mayer; Serge Cremers; Sachin Agarwal; Mitchell S V Elkind; E Sander Connolly; Vanja Dukic; George Hripcsak; Neeraj Badjatia
Journal:  Ann Neurol       Date:  2014-05-16       Impact factor: 10.422

8.  Treatment of status epilepticus: an international survey of experts.

Authors:  James J Riviello; Jan Claassen; Suzette M LaRoche; Michael R Sperling; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Lori Shutter; David M Treiman; Paul M Vespa; Rodney Bell; Gretchen M Brophy
Journal:  Neurocrit Care       Date:  2013-04       Impact factor: 3.210

9.  Atenolol offers better protection than clonidine against cardiac injury in kainic acid-induced status epilepticus.

Authors:  M I Read; J C Harrison; D S Kerr; I A Sammut
Journal:  Br J Pharmacol       Date:  2015-08-24       Impact factor: 8.739

10.  Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

Authors:  Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.